Lugtenburg, Pieternella Johanna; De Nully Brown, Peter; Van der Holt, Bronno; D'Amore, Francesco A.; Koene, Harry R.; De Jongh, Eva; Fijnheer, Rob; Van Esser, Joost W.; Bohmer, Lara H.; Pruijt, Johannes F.; Verhoef, Gregor E.; Hoogendoorn, Mels; Bilgin, Memis Y.; Nijland, Marcel; Van der Burg-De Graauw, Nicole C.; Oosterveld, Margreet; Jie, Kon Siong G.; Larsen, Thomas Stauffer; Van der Poel, Marjolein W.; Leijs, Maria B.; Silbermann, Matthijs H.; Van Marwijk Kooy, Marinus; Beeker, Aart; Kersten, Marie J.; Doorduijn, Jeanette K.; Tick, Lidwine W.; Brouwer, Rolf E.; Lam, King H.; Burggraaff, Coreline N.; De Keizer, Bart; Arens, Anne I.; De Jong, Daphne; Hoekstra, Otto S.; Zijlstra-Baalbergen, Josee M.
(Lippincott Williams & Wilkins, 2020-10-10)
PURPOSE: Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial ...